Interferon Alpha-2a Therapy in Patients with Refractory Behçet Uveitis


Hasanreisoglu M., ÇUBUK M. Ö., ÖZDEK Ş., Gurelik G., Aktas Z., Hasanreisoglu B.

Ocular Immunology and Inflammation, cilt.25, sa.1, ss.71-75, 2017 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.3109/09273948.2015.1133835
  • Dergi Adı: Ocular Immunology and Inflammation
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.71-75
  • Anahtar Kelimeler: Azathioprine, Behcet, cyclosporine, IFN alpha 2a, uveitis
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: To report the results of IFNα2a therapy in patients with Behçet uveitis refractory to azathioprine-cyclosporine combination treatment. Methods: In a retrospective study, 39 patients treated with either azathioprine-cyclosporine combination treatment (group 1, n = 23) or IFNα2a (group 2, n = 16) with a diagnosis of ocular Behçet disease (BD), were included in the study. Group 2 consisted of patients who did not respond to conventional combination therapy, and were therefore treated with IFNα2a. Clinical response and relapse rates were recorded for each group. Results: The mean number of uveitis attacks/year per patient was 0.8 ± 1.6 in Group 1. In Group 2, a significant decrease in the mean number of uveitis attacks/year per patient was observed after initiation of IFNα2a (2.4 ± 1.8 vs 1.3 ± 2.0) (p<0.05). When the two groups were compared after administration of IFNα2a therapy, no statistical difference was found in terms of uveitis attack/year and attack-free intervals, with a partial response to both treatments. Conclusions: IFNα2a therapy is an effective alternative for Behçet uveitis patients where conventional combination therapy fails.